Glaukos Corp. (GKOS), a pharmaceutical and medical technology company focused on ophthalmic therapies, secured FDA approval on October 20 for Epioxa, its non-invasive topical therapy for keratoconus. The announcement follows steady Q2 revenue growth and precedes a key regulatory decision for iDose TR, expected by December 20. With multiple programs in development and a new manufacturing site underway, Glaukos continues to execute across clinical, regulatory, and operational fronts.
FDA Approves Epioxa for Keratoconus
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com